Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02666248 · ClinicalTrials.gov registry record
Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 3
- Enrollment target
NCT02666248: Completed study, sponsored by University of Pennsylvania.
NCT02666248 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02666248 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 3 participants
- Enrollment target
Study Summary
This is a non-therapeutic, long-term follow-up (LTFU) study of subjects who have received retroviral-based gene therapy products in cancer studies. All subjects in this LTFU protocol have received lentiviral modified T cells engineered to express an anti-EGFRvIII scFv Chimeric Antigen Receptor (CAR).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-05-23 |
| Est. Completion | 2018-01-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02666248
The ClinicalTrials.gov registry entry for NCT02666248 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02666248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02666248 about?
NCT02666248 is a clinical study titled "Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies". This is a non-therapeutic, long-term follow-up (LTFU) study of subjects who have received retroviral-based gene therapy products in cancer studies. All subjects in this LTFU protocol have received lentiviral modified T cells engineered to express an anti-EGFRvIII scFv Chimeric Antigen Receptor (CAR)...
What is the current status of trial NCT02666248?
This trial is currently completed. The enrollment target is 3 participants. The study started on 2016-05-23. Estimated completion is 2018-01-27.
Who is sponsoring clinical trial NCT02666248?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.